Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Posted on 30/06/2025 by Neuroscientists

Dr. Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Dr. Ling-Yan Su, Yunnan Agricultural University, China.

Professor Ling-Yan Su is a leading figure in the field of food science and plant physiology, currently serving at the College of Food Science and Technology, Yunnan Agricultural University. With a solid academic foundation from Yunnan University and the Chinese Academy of Sciences, she has built a dynamic career that bridges molecular biology and applied agricultural research. Her pioneering work on melatonin-based pre-harvest treatments has significantly advanced our understanding of natural preservation techniques, especially in prolonging the post-harvest life and quality of fruits like Myrica rubra. Her research focuses on enhancing antioxidant systems, inhibiting spoilage, and activating plant defense pathways through sustainable, low-toxicity treatments.

Profile

Google Scholar

🎓 Early Academic Pursuits

Ling-Yan Su’s journey in the biological sciences began with a Bachelor of Science degree from the School of Life Science at Yunnan University (2007–2011). Demonstrating academic curiosity and determination early on, she expanded her horizons through a year-long visiting student program (2010–2011) at the prestigious Kunming Institute of Zoology, affiliated with the Chinese Academy of Sciences. This experience laid the foundation for her doctoral research, which she pursued at the same institute from 2011 to 2017, where she rigorously explored complex biological systems, further solidifying her passion for food science and plant physiology.

🧪 Professional Endeavors in Science

Professor Su’s professional career has been marked by consistent growth across esteemed academic institutions. Following her Ph.D., she joined the Kunming Institute of Zoology as a research assistant, rapidly advancing to the role of associate professor. In 2022, she transitioned to the College of Food Science and Technology at Yunnan Agricultural University, initially as an associate professor before her promotion to full professor within the same year. Her academic trajectory reflects a blend of deep research engagement and an evolving role in shaping food science education and innovation in China.

🌿 Contributions and Research Focus

Professor Su’s groundbreaking work lies at the intersection of plant physiology, post-harvest fruit biology, and food preservation technology. She has made significant contributions to understanding how melatonin, a naturally occurring compound, can be leveraged to extend the post-harvest shelf life of Myrica rubra (Chinese bayberry). Her studies demonstrate that melatonin pre-harvest treatments reduce oxidative stress markers, inhibit microbial decay, and activate the phenylpropanoid pathway, resulting in elevated antioxidant activity. This line of research not only reveals novel mechanisms of fruit preservation but also opens sustainable avenues in post-harvest biology and food safety.

🏅 Accolades and Recognition

While formal awards are not listed, Professor Su’s rapid academic promotions and appointments at prestigious research institutes such as the Chinese Academy of Sciences and Yunnan Agricultural University underscore her recognition within the scientific community. Her work is contributing to a growing body of literature on sustainable food science innovations, earning her esteem among peers and collaborators in the agricultural biotechnology field.

🌱 Impact and Influence

Professor Su’s innovative application of melatonin in fruit preservation has substantial implications for food technology and agricultural practices. Her research directly addresses global concerns such as food spoilage, post-harvest losses, and chemical-free preservation methods. By enhancing natural antioxidant defenses and inhibiting spoilage at a molecular level, her work supports both farmers and consumers in accessing healthier and longer-lasting produce, especially within the context of environmentally conscious food systems.

🔬 Legacy in Food Science

The legacy Professor Su is building centers around translating scientific inquiry into practical solutions for real-world agricultural challenges. Her research is charting a course for future studies in the bio-preservation of fruits and vegetables using natural treatments. As she continues to mentor students and collaborate across disciplines, her influence is extending into the next generation of food scientists and researchers focused on plant biochemistry, post-harvest technology, and sustainable agricultural innovation.

🚀 Future Contributions and Vision

Looking ahead, Professor Ling-Yan Su is poised to further explore how endogenous compounds like melatonin can be applied across various fruits and food crops. Her vision includes broadening the scope of natural food preservation strategies and delving deeper into molecular pathways that regulate plant defense responses. As a respected academic and scientist, her future contributions are expected to shape healthier food systems and deepen scientific understanding of plant–microbe–compound interactions.

Publication

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Authors: DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, …
Year: 2021

Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
Authors: R Luo, LY Su, G Li, J Yang, Q Liu, LX Yang, DF Zhang, H Zhou, M Xu, …
Year: 2020

Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation
Authors: LY Su, H Li, L Lv, YM Feng, GD Li, R Luo, HJ Zhou, XG Lei, L Ma, JL Li, …
Year: 2015

Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin
Authors: YM Feng, YF Jia, LY Su, D Wang, L Lv, L Xu, YG Yao
Year: 2013

Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China
Authors: D Wang, L Xu, L Lv, LY Su, Y Fan, DF Zhang, R Bi, D Yu, W Zhang, XA Li, …
Year: 2015

Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine
Authors: LY Su, R Luo, Q Liu, JR Su, LX Yang, YQ Ding, L Xu, YG Yao
Year: 2017

Positive selection rather than relaxation of functional constraint drives the evolution of vision during chicken domestication
Authors: MS Wang, R Zhang, LY Su, Y Li, MS Peng, HQ Liu, L Zeng, DM Irwin, …
Year: 2016

Melatonin alleviates morphine analgesic tolerance in mice by decreasing NLRP3 inflammasome activation
Authors: Q Liu, LY Su, C Sun, L Jiao, Y Miao, M Xu, R Luo, X Zuo, R Zhou, P Zheng, …
Year: 2020

Out of Southern East Asia of the brown rat revealed by large-scale genome sequencing
Authors: L Zeng, C Ming, Y Li, LY Su, YH Su, NO Otecko, A Dalecky, S Donnellan, …
Year: 2018

Moringa oleifera Lam. leaves as new raw food material: A review of its nutritional composition, functional properties, and comprehensive application
Authors: M Yang, L Tao, XR Kang, ZL Wang, LY Su, LF Li, F Gu, CC Zhao, J Sheng, …
Year: 2023

✅ Conclusion

Professor Su’s academic journey and research contributions exemplify scientific excellence rooted in sustainability and innovation. Her work not only provides practical solutions to post-harvest challenges but also contributes to broader efforts in reducing food waste and promoting natural preservation methods. As she continues to mentor young researchers and expand her studies, Professor Su is well-positioned to leave a lasting impact on food science and agricultural biotechnology. Her career reflects a thoughtful integration of research, application, and forward-looking vision in the quest for healthier and more resilient food systems.

Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Posted on 11/06/202511/06/2025 by Neuroscientists

Prof.Dr. Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Prof. Dr. Rosario Osta, CIBERNED-Fundación Instituto de Investigación Sanitaria de Aragón-Universidad de Zaragoza, Spain.

Prof. Rosario Osta Pinzolas is a distinguished geneticist and full professor at the University of Zaragoza, Spain. Her academic roots in veterinary sciences and a Ph.D. in Genetics laid the foundation for a prolific career in biomedical research, particularly in the fields of neuroscience and genetic disorders. With leadership roles in multiple high-profile research consortia such as CIBERNED, TRICALS, and ENCALS, she has established herself as a central figure in neurodegenerative disease research. Her scholarly output includes over 100 indexed publications, multiple national and international research projects, and an h-index exceeding 45.

Profile

Orcid

Scopus

🎓 Early Academic Pursuits

Rosario Osta Pinzolas began her academic journey with a solid foundation in veterinary sciences, graduating as Licenciada en Veterinaria from the University of Zaragoza in 1989. Her academic inclinations quickly shifted toward molecular genetics, leading her to complete a Ph.D. in Genetics at the same university in 1994. Her early studies were driven by a deep curiosity about the mechanisms of heredity and gene expression, setting the tone for a lifelong commitment to biomedical research. These formative years cultivated her scientific rigor and sowed the seeds for a career that would eventually bridge basic science and translational medicine.

🧬 Professional Endeavors in Genetics and Biomedicine

Prof. Osta currently holds the esteemed title of Catedrática (Full Professor) in the Department of Anatomy, Embryology, and Genetics at the Faculty of Veterinary Medicine, University of Zaragoza. Since 2018, she has led her department with a focus on integrative biomedical sciences. She is the principal investigator of the LAGENBIO group recognized by both the Aragon Health Research Institute and the Government of Aragon. Under her leadership, the group has developed two major subprograms: TERAGEN and REGENERAGEN. As coordinator of the “Neuroscience and Mental Health Program” at IISA, she has spearheaded numerous efforts to understand and address neurological diseases through genetic approaches.

🧠 Contributions and Research Focus in Neuroscience

A prominent figure in neuroscience, Prof. Osta’s research lies at the intersection of genetics and neurodegeneration. She is currently the principal investigator of the only Aragon-based group within CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), reflecting her national influence. Her team represents Zaragoza in prominent European consortia such as TRICALS and ENCALS, both focused on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Through more than 100 indexed publications, predominantly in top-tier journals, her work delves into the molecular underpinnings of neurological disorders and explores regenerative medicine strategies, thereby contributing to innovative therapeutic avenues.

🧪 Accolades and Recognition in Scientific Excellence

Prof. Osta’s academic and research career has been punctuated by consistent recognition. She has completed five research productivity periods and one technology transfer period, acknowledged by CNEAI — a mark of sustained scientific impact. She has led over 74 research projects and contributed to more than 100 collaboration contracts, earning her four competitive research awards from respected institutions including CORIS, AREA, IIS, and SEBBM. Her contributions have been lauded not only for scientific quality but also for practical relevance in biomedical advancements.

🚀 Innovation and Impact in Translational Research

An ardent advocate for science with societal impact, Prof. Osta has significantly contributed to technology transfer. She holds nine patents, five of which have been licensed to industry partners. Her collaborations with companies have led to meaningful translational outputs, emphasizing her role in bridging the gap between academic research and real-world solutions. As former Director of the Technology Transfer and Innovation Secretariat at the University of Zaragoza for nearly a decade, she played a crucial role in institutional innovation strategies. Her involvement in joint university-company chairs and her role in the UZ Technology-Based Business Creation Committee for over 12 years further underscore her influence on academic entrepreneurship.

📚 Mentorship and Educational Leadership

Beyond the lab, Prof. Osta has left a profound mark as an educator and mentor. Since 2013, she has coordinated the Interuniversity Doctoral Program in Biomedical and Biotechnological Sciences, a joint initiative between the Universities of Zaragoza and La Rioja. Her mentorship includes the supervision of 13 Ph.D. theses — 9 of which earned international distinction and 6 received extraordinary doctoral awards. Her influence extends to guiding numerous undergraduate and master’s theses, fostering a new generation of scientists with a deep commitment to research excellence and innovation.

🌍 Legacy and Future Contributions

Prof. Rosario Osta’s legacy is defined by her ability to integrate scientific discovery, mentorship, and innovation. As a member of the Scientific Committee of the Luzón Foundation, her vision reaches beyond academia into public health advocacy and strategic research planning. With nearly 19,000 citations on Google Scholar and an h-index of 45, her work continues to inspire and inform global research communities. Her continued leadership in collaborative European projects ensures her contributions will shape the future of neuroscience, genetics, and translational medicine for years to come.

Publication

Title: Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Authors: L. Moreno-Martinez, N. Gaja-Capdevila, L. Mosqueira-Martín, R. Osta, F.J. Gil-Bea
Year: 2025

Title: Identifying Hub Genes and miRNAs Associated with Alzheimer’s Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies
Authors: E. Gascón, A.C. Calvo, N. Molina, P. Zaragoza, R. Osta
Year: 2024

Title: Comparative Blood Profiling Based on ATR-FTIR Spectroscopy and Chemometrics for Differential Diagnosis of Patients with Amyotrophic Lateral Sclerosis—Pilot Study
Authors: K. Tkachenko, J.M. González Sáiz, A.C. Calvo, R. Osta, C. Pizarro Millán
Year: 2024

Title: Sex differences on constitutive long non-coding RNA expression: Modulatory effect of estradiol and testosterone in muscle cells
Authors: T. López-Royo, L. Moreno-Martinez, L. Moreno-García, R. Manzano, R. Osta
Year: 2024

Title: Differentially expressed lncRNAs in SOD1 G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic lateral sclerosis
Authors: T. López-Royo, L. Moreno-Martinez, P. Zaragoza, R. Manzano, R. Osta
Year: 2024

Title: Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia
Authors: P. Aparicio, D. Navarrete-Villanueva, A. Gómez-Cabello, R. Osta, R. Manzano
Year: 2024

Title: Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes
Authors: E. Gascón, P. Zaragoza, A.C. Calvo, R. Osta
Year: 2024

Title: Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population
Authors: D. Borrego-Hernández, J.F. Vázquez-Costa, R. Domínguez Rubio, M. Povedano, A. García-Redondo
Year: 2024

Title: New Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis
Authors: L. Moreno-Martinez, S. Macías-Redondo, M.H.P. Strunk, R. Osta, J. Schoorlemmer
Year: 2024

Title: Analysis of Plasma-Derived Exosomal MicroRNAs as Potential Biomarkers for Canine Idiopathic Epilepsy
Authors: M. García-Gracia, L. Moreno-Martinez, A. Hernaiz, S. García-Belenguer, I. Martín-Burriel
Year: 2024

🏆 Conclusion

Based on her outstanding research contributions, innovation in translational science, mentorship record, and leadership within national and European research programs, Prof. Rosario Osta Pinzolas is an exceptionally strong candidate for the Best Researcher Award. Her profile reflects not only academic excellence but also societal impact and visionary leadership. While there is room for enhanced global outreach, her sustained achievements and contributions make her highly deserving of this prestigious recognition.

Hao Lai | Clinical Neuroscience | Best Researcher Award

Posted on 29/04/2025 by Neuroscientists

Prof. Dr. Hao Lai | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Hao Lai, Zhongshan Hospital, Fudan University, China.

Dr. Hao Lai is a distinguished cardiovascular surgeon and researcher, currently serving as Chief Physician at Zhongshan Hospital, Fudan University. With over 20 years of clinical expertise, he specializes in aortic and cardiovascular surgery. His academic achievements include a Ph.D. in Surgery from Fudan University and significant contributions to the study of epigenetic mechanisms in thoracic aortic dissection. As a principal investigator of nationally funded projects and co-author of influential publications, Dr. Lai combines scientific rigor with clinical innovation. He has also played a key role in medical education and device development through industry collaboration.

Profile

Scopus

🎓 Early Academic Pursuits

Dr. Hao Lai began his academic journey with a strong foundation in medical sciences, culminating in a Ph.D. in Surgery from the prestigious Fudan University. His early academic pursuits were marked by a deep interest in cardiovascular physiology and surgical intervention, which later matured into a specialized focus on aortic diseases. His time as a doctoral candidate not only equipped him with rigorous scientific training but also ignited his lifelong commitment to solving complex clinical problems through research.

🏥 Professional Endeavors

Currently serving as Chief Physician at Zhongshan Hospital, Fudan University, Dr. Hao Lai has accumulated over two decades of extensive clinical experience in cardiovascular and aortic surgery. His professional trajectory reflects a seamless integration of surgical excellence with academic leadership. At Zhongshan Hospital, a leading institution in China, he has spearheaded several clinical programs aimed at enhancing patient outcomes in cases of thoracic aortic dissection and other high-risk cardiovascular conditions.

🔬 Contributions and Research Focus

Dr. Lai’s research centers around the epigenetic mechanisms underlying thoracic aortic dissection, with a particular focus on histone modification and DNA methylation. He is the Principal Investigator of a major research project funded by the National Natural Science Foundation of China, which explores the role of H3K36me3 histone modification and DNMT3B-mediated gene body methylation in the pathogenesis of aortic dissection. His scientific efforts bridge molecular pathology with clinical implications, offering new perspectives on the diagnosis and treatment of life-threatening vascular disorders.

🏆 Accolades and Recognition

A respected voice in cardiovascular medicine, Dr. Hao Lai has co-authored numerous influential articles in high-impact journals such as Cardiovascular Research and Advanced Science. His h-index of 18, as listed on Scopus, reflects his consistent scholarly output and the wide academic acknowledgment of his work. In addition, his authorship of the textbook Practical Surgery (3rd Edition), published by People’s Medical Publishing House, stands as a testament to his educational contributions to the next generation of Chinese surgeons.

🧪 Impact and Innovation

Dr. Lai’s research has made a tangible impact on the understanding and treatment of aortic diseases. His investigation into the epigenetic regulation of vascular pathology has opened new avenues for targeted therapies. Moreover, his collaboration with MicroPort Endovascular MedTech demonstrates his commitment to translating research findings into real-world applications, particularly in the development and refinement of endovascular surgical devices.

🌍 Influence and Collaboration

Beyond his direct research and surgical contributions, Dr. Lai’s influence extends into collaborative domains, both nationally and internationally. His leadership in high-level research grants, clinical trials, and industrial partnerships positions him as a central figure in the evolving landscape of cardiovascular surgery. His collaborative spirit fosters innovation and promotes cross-disciplinary dialogue, essential in today’s complex medical research environment.

🔮 Legacy and Future Contributions

As Dr. Hao Lai continues his distinguished career, his legacy is being shaped not only by his surgical accomplishments but also by his contributions to medical science. His ongoing projects are likely to further clarify the molecular landscape of aortic diseases and inspire new therapeutic strategies. Looking ahead, Dr. Lai is poised to remain at the forefront of cardiovascular innovation, committed to improving patient care through a synthesis of research, education, and clinical practice.

Publication

Title: Prevalence and predictors of left atrial thrombus in patients with rheumatic atrial fibrillation undergoing cardiac surgery: a cross-sectional study
Authors: J. Cui, Y. Zhang, Y. Wang, Q. Ji, C. Wang
Year: 2025

Title: A novel open-vascular single-branched stent graft in total arch repair of type A aortic dissection one-year results of a prospective multicenter randomized controlled study
Authors: J. Gu, W. Zhang, L. Kang, H. Lai, C. Wang
Year: 2025

Title: Fibroblast Activation Protein Acts as a Biomarker for Monitoring ECM Remodeling During Aortic Aneurysm via 68Ga-FAPI-04 PET Imaging
Authors: C. Hu, H. Tan, Y. Zhang, X. Chen, L. Wang
Year: 2025

Title: Mitochondrial NAD+ deficiency in vascular smooth muscle impairs collagen III turnover to trigger thoracic and abdominal aortic aneurysm
Authors: J. Zhang, Y. Tang, S. Zhang, K. Zhu, W. Zhang
Year: 2025

Title: Correcting mitochondrial loss mitigates NOTCH1-related aortopathy in mice
Authors: Y. Tang, J. Zhang, Y. Fang, Y. Xu, W. Zhang
Year: 2025

Title: Exploration of 68Ga-FAPI-04 PET/MR in Chronic Type B Aortic Dissection
Authors: C. Hu, Y. Zhang, S. Qiu, H. Shi, L. Wang
Year: 2025

Title: Effects of postoperative glucocorticoids on mitigation of organ dysfunction in patients with type A aortic dissection: A randomized controlled trial
Authors: M. Luo, J. Luo, X. Xu, G. Tu, Z. Luo
Year: 2024

Title: Therapeutic results of three-dimensional aortic valve anatomic repair for regurgitant bicuspid aortic valve
Authors: J. Li, C. Wang, Z. Zuo, W. Ding, T. Hong
Year: 2024

Title: 68Ga-FAPI-04 Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Ascending Aortic Aneurysm
Authors: C. Hu, H. Tan, Y. Zhang, H. Lai, L. Wang
Year: 2024

Title: Sex-based outcomes after thoracic endovascular aortic repair: A systematic review and meta-analysis
Authors: Y. Zhang, Y. Zhang, Y. Wang, L. Wang, Q. Ji
Year: 2025

✅ Conclusion

Dr. Hao Lai’s career represents a powerful blend of surgical precision, scientific insight, and academic leadership. His work has advanced the understanding of aortic diseases at the molecular level while improving surgical outcomes for patients. As he continues to mentor, innovate, and lead research at the intersection of epigenetics and cardiovascular pathology, Dr. Lai’s contributions are set to leave a lasting legacy in both clinical practice and medical science.

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Posted on 21/04/202521/04/2025 by Neuroscientists

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
Year: 2017

Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
Authors: Wu G, Wu Z, Na S, Hershey JC
Year: 2015

Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
Year: 2005

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Posted on 17/02/202517/02/2025 by Neuroscientists

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

Publication

Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
Year: 2025

The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
Year: 2023

Nonviral delivery systems for antisense oligonucleotide therapeutics
Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
Year: 2022

The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
Year: 2022

Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
Authors: Not explicitly listed
Year: 2021

Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
Year: 2021

Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
Year: 2020

Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
Authors: Not explicitly listed
Year: 2019

Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
Year: 2019

Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
Authors: Not explicitly listed
Year: 2018

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.